论文部分内容阅读
目的研究HP方案治疗38例晚期非小细胞肺癌(NSCLC)的临床疗效及毒副作用。方法羟基喜树碱(HCPT)10mg·m-·2d-1,静脉滴注,第1￣5天;顺铂(DDP)20mg·m-·2d-1,静脉滴注,第1￣5天;21d为1个周期,连用3个周期。结果38例CR13.2%(5/38),PR39.5%(15/38),SD36.8%(14/38),PD10.5%(4/38),总有效率52.6%(20/38)。结论HCPT联合DDP的HP方案治疗晚期NSCLC为较有效方案,毒性低,值得临床推广研究。
Objective To study the clinical efficacy and side effects of HP regimen in the treatment of 38 patients with advanced non-small cell lung cancer (NSCLC). Methods HCPT 10mg · m- · 2d-1, intravenous drip, 1st to 5th days; cisplatin (DDP) 20mg · m- · 2d-1, intravenous drip, ; 21d for a period, once every 3 cycles. Results 38 cases had CR13.2% (5/38), PR39.5% (15/38), SD36.8% (14/38) and PD10.5% (4/38), and the total effective rate was 52.6% (20 / 38). Conclusion HCPT combined with DDP HP regimen for advanced NSCLC is more effective, low toxicity, worthy of clinical research.